Skip to main content

COMMITTED TO PATIENT ACCESS AND SUPPORT

Best access among specialty systemic therapies indicated for PN1,a,b Most efficient path to starting treatment for most patientsc

≈98% of commercial patients (18+ years of age) nationally are covered for DUPIXENT1,a ≈91% of commercial patient lives have to fail only 1 or 2 prescription topical treatments1,a

The formulary status tool below can help check DUPIXENT coverage for various plans. Contact the health plan or DUPIXENT MyWay ​® to verify coverage for a specific patient.

  • aMMIT Analysis, June 2025. Analysis included DUPIXENT and nemolizumab.
  • bBased on available published commercial UM coverage criteria.
  • cLeast step edits to biologics in PN.
icon search

Check the formulary status for DUPIXENT in your area

See coverage status, prior authorization, and step therapy information

US.DUP.25.06.0474

Questions?

For questions or a full benefits investigation for your patient, contact
DUPIXENT MyWay®
at 1‑844‑DUPIXEN(T) 
(1‑844‑387‑4936), Monday‑Friday,
8am–9pm ET